Perioperative Chemotherapy for Gastro-Esophageal or Gastric Cancer: Anthracyclin Triplets versus FLOT

被引:0
|
作者
Geerts, Julie F. M. [1 ,2 ]
van der Zijden, Charlene J. [2 ]
van der Sluis, Pieter C. [2 ]
Spaander, Manon C. W. [3 ]
Nieuwenhuijzen, Grard A. P. [1 ]
Rosman, Camiel [4 ]
van Laarhoven, Hanneke W. M. [5 ,6 ]
Verhoeven, Rob H. A. [5 ,6 ,7 ]
Wijnhoven, Bas P. L. [2 ]
Lagarde, Sjoerd M. [2 ]
Mostert, Bianca [8 ]
机构
[1] Catharina Hosp, Dept Surg, NL-5623 EJ Eindhoven, Netherlands
[2] Erasmus MC, Dept Surg, Canc Inst, NL-3015 GD Rotterdam, Netherlands
[3] Erasmus MC, Dept Gastroenterol & Hepatol, NL-3015 GD Rotterdam, Netherlands
[4] Radboud Univ Nijmegen, Dept Surg, Med Ctr, NL-6525 GA Nijmegen, Netherlands
[5] Univ Amsterdam, Dept Med Oncol, Amsterdam UMC Locat, NL-1081 HV Amsterdam, Netherlands
[6] Canc Ctr Amsterdam, Canc Treatment & Qual Life, NL-1105 AZ Amsterdam, Netherlands
[7] Netherlands Comprehens Canc Org IKNL, Dept Res & Dev, NL-3511 LC Utrecht, Netherlands
[8] Erasmus MC, Dept Med Oncol, Canc Inst, NL-3015 GD Rotterdam, Netherlands
关键词
esophageal cancer; gastro-esophageal cancer; gastric cancer; neoadjuvant chemotherapy; esophagectomy; STAGING LAPAROSCOPY; ADENOCARCINOMA; SURVIVAL; 5-FLUOROURACIL; CAPECITABINE; OXALIPLATIN;
D O I
10.3390/cancers16071291
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The FLOT4-AIO trial (2019) showed improved survival with perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) compared to anthracyclin triplets in gastric cancer treatment. It is unclear whether these results extend to real-world scenarios in the Netherlands. This study aimed to compare outcomes of perioperative FLOT to anthracyclin triplets in a real-world Dutch gastric cancer population. Methods: Patients diagnosed with resectable (cT2-4a/cTxN0-3/NxM0) gastric or gastro-esophageal junction carcinoma between 2015-2021 who received neoadjuvant FLOT or anthracyclin triplets were selected from the Netherlands Cancer Registry. The primary outcome was overall survival (OS), analyzed through multivariable Cox regression. Secondary outcomes included pathological complete response (pCR), neoadjuvant chemotherapy cycle completion, surgical resection rates, and adjuvant therapy. Results: Adjusted OS showed no significant survival benefit (HR = 0.88, 95% CI 0.77-1.01, p = 0.07), even though the median OS was numerically improved by 8 months with FLOT compared to anthracyclin triplets (48.1 vs. 39.9 months, p = 0.16). FLOT patients were more likely to undergo diagnostic staging laparoscopies (74.2% vs. 44.1%, p < 0.001), had higher rates of completing neoadjuvant chemotherapy (OR = 1.35, 95% CI 1.09-1.68, p = 0.007), receiving adjuvant therapy (OR = 1.34, 95% CI 1.08-1.66, p = 0.08), and achieving pCR (OR = 1.52, 95% CI 1.05-2.20, p = 0.03). No significant differences were observed in (radical) resection rates. Conclusion(s): Real-world data showed no significant OS improvement for FLOT-treated patients compared to anthracyclin triplets, despite more staging laparoscopies. However, FLOT patients demonstrated higher rates of neoadjuvant therapy completion, proceeding to adjuvant therapy, and increased pCR rates. Therefore, we recommend the continued use of neoadjuvant FLOT therapy in the current clinical setting.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Perioperative chemotherapy for operable gastroesophageal or gastric cancer: Anthracycline triplets versus FLOT
    van der Zijden, C.
    Geerts, J.
    van der Sluis, P.
    Spaander, M.
    Nieuwenhuijzen, G.
    Rosman, C.
    van Laarhoven, H.
    Verhoeven, R.
    Wijnhoven, B.
    Lagarde, S.
    Mostert, B.
    ANNALS OF ONCOLOGY, 2023, 34 : S150 - S150
  • [2] Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol
    Huemer, F.
    Hecht, S.
    Scharinger, B.
    Schlintl, V.
    Rinnerthaler, G.
    Schlick, K.
    Heregger, R.
    Melchardt, T.
    Wimmer, A.
    Muehlbacher, I.
    Koch, O.
    Neureiter, D.
    Klieser, E.
    Seyedinia, S.
    Beheshti, M.
    Greil, R.
    Weiss, L.
    ANNALS OF ONCOLOGY, 2022, 33 : S268 - S268
  • [3] Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol
    Huemer, Florian
    Hecht, Stefan
    Scharinger, Bernhard
    Schlintl, Verena
    Rinnerthaler, Gabriel
    Schlick, Konstantin
    Heregger, Ronald
    Melchardt, Thomas
    Wimmer, Angela
    Muehlbacher, Iris
    Koch, Oliver Owen
    Neureiter, Daniel
    Klieser, Eckhard
    Seyedinia, Sara
    Beheshti, Mohsen
    Greil, Richard
    Weiss, Lukas
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (07) : 3051 - 3064
  • [4] Body composition dynamics and impact on clinical outcome in gastric and gastro-esophageal junction cancer patients undergoing perioperative chemotherapy with the FLOT protocol
    Florian Huemer
    Stefan Hecht
    Bernhard Scharinger
    Verena Schlintl
    Gabriel Rinnerthaler
    Konstantin Schlick
    Ronald Heregger
    Thomas Melchardt
    Angela Wimmer
    Iris Mühlbacher
    Oliver Owen Koch
    Daniel Neureiter
    Eckhard Klieser
    Sara Seyedinia
    Mohsen Beheshti
    Richard Greil
    Lukas Weiss
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 3051 - 3064
  • [5] Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial
    Yuan, Shu-Qiang
    Nie, Run-Cong
    Jin, Ying
    Liang, Cheng-Cai
    Li, Yuan-Fang
    Jian, Rui
    Sun, Xiao-Wei
    Chen, Ying-Bo
    Guan, Wen-Long
    Wang, Zi-Xian
    Qiu, Hai-Bo
    Wang, Wei
    Chen, Shi
    Zhang, Dong-Sheng
    Ling, Yi-Hong
    Xi, Shao-Yan
    Cai, Mu-Yan
    Huang, Chun-Yu
    Yang, Qiu-Xia
    Liu, Zhi-Min
    Guan, Yuan-Xiang
    Chen, Yong-Ming
    Li, Ji-Bin
    Tang, Xiong-Wen
    Peng, Jun-Sheng
    Zhou, Zhou-Wei
    Xu, Rui-Hua
    Wang, Feng
    NATURE MEDICINE, 2024, 30 (02) : 552 - 559
  • [6] Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial
    Shu-Qiang Yuan
    Run-Cong Nie
    Ying Jin
    Cheng-Cai Liang
    Yuan-Fang Li
    Rui Jian
    Xiao-Wei Sun
    Ying-Bo Chen
    Wen-Long Guan
    Zi-Xian Wang
    Hai-Bo Qiu
    Wei Wang
    Shi Chen
    Dong-Sheng Zhang
    Yi-Hong Ling
    Shao-Yan Xi
    Mu-Yan Cai
    Chun-Yu Huang
    Qiu-Xia Yang
    Zhi-Min Liu
    Yuan-Xiang Guan
    Yong-Ming Chen
    Ji-Bin Li
    Xiong-Wen Tang
    Jun-Sheng Peng
    Zhi-Wei Zhou
    Rui-Hua Xu
    Feng Wang
    Nature Medicine, 2024, 30 : 552 - 559
  • [7] Perioperative chemotherapy for gastric cancer in FLOT4
    Roviello, Giandomenico
    Roviello, Franco
    Mini, Enrico
    LANCET, 2020, 395 (10218): : E3 - E3
  • [8] Ramucirumab for the treatment of gastric or gastro-esophageal junction cancer
    Khan, Uqba
    Shah, Manish A.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (11) : 1135 - 1141
  • [9] Author Correction: Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial
    Shu-Qiang Yuan
    Run-Cong Nie
    Ying Jin
    Cheng-Cai Liang
    Yuan-Fang Li
    Rui Jian
    Xiao-Wei Sun
    Ying-Bo Chen
    Wen-Long Guan
    Zi-Xian Wang
    Hai-Bo Qiu
    Wei Wang
    Shi Chen
    Dong-Sheng Zhang
    Yi-Hong Ling
    Shao-Yan Xi
    Mu-Yan Cai
    Chun-Yu Huang
    Qiu-Xia Yang
    Zhi-Min Liu
    Yuan-Xiang Guan
    Yong-Ming Chen
    Ji-Bin Li
    Xiong-Wen Tang
    Jun-Sheng Peng
    Zhi-Wei Zhou
    Rui-Hua Xu
    Feng Wang
    Nature Medicine, 2024, 30 : 605 - 605
  • [10] Palliative Chemotherapy and Targeted Therapies for Esophageal and Gastro-Esophageal Junction Cancer
    Janmaat, Vincent
    Bruno, Marco J.
    Peppelenbosch, Maikel
    Mathijssen, Ron
    van der Gaast, Ate
    Steyerberg, Ewout
    Kuipers, Ernst J.
    Spaander, Manon
    GASTROENTEROLOGY, 2016, 150 (04) : S652 - S652